Ronald Reagan UCLA Medical Center has performed its first procedure to remove a patient's diseased heart and replace it with a SynCardia Temporary Total Artificial Heart.
Chad Washington, 35, underwent the seven-hour transplant surgery at UCLA on Oct. 29, led by Dr. Murray Kwon, an assistant professor of cardiothoracic surgery.
The temporary pump will act as a "bridge" until Washington receives a new donor heart.
"Historically, patients with a total artificial heart had to remain hospitalized while they waited for a transplant because they were tethered to a large machine to power the device," Kwon said. "Today, however, this device can be powered by advanced technology small enough to fit in a backpack."
"It sounds like a loud grandfather clock going 'tick-tock' in my chest, but it doesn't feel foreign. It's there to help," Washington said of the artificial heart. "I'm so glad to be living in an age where technology is moving so fast."
Thankfully, the artificial heart offered hope.
"By removing the patient's diseased donor heart, we removed the source of his end-stage heart failure," said Dr. Ali Nsair, an assistant professor of cardiology at UCLA. "The total artificial heart — and being off immunosuppressant medications — allows his body to recover and get ready for a heart transplant in a few months."
Dr. Mario Deng, a professor of cardiology and medical director of the UCLA Advanced Heart Failure/Mechanical Support/Heart Transplant Program added that since the pump's energy source is portable, Washington can go home and resume normal activities with his family while he waits for a new heart.
"This ability to be at home with family is an important element in helping the patient to maintain a positive outlook during the waiting period," Deng said.
Approved by the Federal Drug Administration in 2004, the SynCardia Total Artificial Heart replaces both failing heart ventricles and the four heart valves. It works by providing a high volume of blood-flow through both ventricles, which helps to speed the recovery of vital organs and make the patient a better candidate for transplant surgery.
Once the total artificial heart is implanted, it is connected by two small air tubes known as "drivelines" to a large external driver that powers the heart while the patient remains hospitalized. When the patient's condition stabilizes post-operatively, he or she can be switched over to the smaller 13.5-pound Freedom portable driver, which can be carried in a backpack, thus giving the patient the freedom to leave the hospital.
"This technology offers a lifeline for patients who are in severe heart failure and dying," said Dr. Richard J. Shemin, professor and chair of cardiothoracic surgery at UCLA and surgical director of the UCLA Mechanical Circulatory Support Program. "These patients have run out of medical options and require a heart transplant. The total artificial heart offers advantages over other devices used for mechanical support of patients awaiting a heart transplant. With the new Freedom driver for powering the device, the patients can leave the hospital, live at home and undergo rehabilitation, improving their clinical condition and quality of life as they await their transplant."
Originally used as a permanent replacement heart, SynCardia's Total Artificial Heart is currently approved as a bridge to transplant for people dying from end-stage biventricular heart failure. There have been more than 1,000 implants of the Total Artificial Heart worldwide, accounting for more than 270 patient-years of life. The wearable driver is currently undergoing an U.S. Food and Drug Administration–approved investigational device exemption clinical study. For more information, visit www.syncardia.com.
The UCLA Mechanical Circulatory Support Program, directed by Dr. Richard Shemin, professor and chief of cardiothoracic surgery at UCLA, and Dr. Mario Deng, professor of cardiology and medical director of the advanced heart failure/mechanical support/heart transplant program, began in the early 1990s. Its primary mission is to provide cardiac support devices to patients while they await heart transplantation and to serve the rapidly growing heart failure population requiring lifetime mechanical circulatory support. For more information on the mechanical circulatory program and the heart transplant program at UCLA.